BACKGROUND Assessment of the efficacy of a multi-agent chemotherapy protocol in which cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) are administered in canine lymphoma is generally performed by physical measurement of lymph node diameter. However, no consistent correlation has been made with prognostic indicators and the length or absence of clinical remission based on lymph node size. RNA disruption measured mid-therapy has been correlated with increased disease-free survival in recent studies of human cancer and was assessed in this study of canine lymphoma patients. Fine needle aspirate samples were taken before treatment and at weeks 3, 6, and 11 of CHOP therapy. RNA was isolated from these samples and assessed using an Agilent Bioanalyzer. RNA disruption assay (RDA) analysis was performed on the data from the resulting electropherograms. RESULTS An increased RNA disruption index (RDI) score was significantly associated with improved progression-free survival. CONCLUSIONS Predicting the risk of early relapse during chemotherapy could benefit veterinary patients by reducing ineffective treatment and could allow veterinary oncologists to switch earlier to a more effective drug regimen.

中文翻译：

---

RNA破坏表明CHOP治疗犬淋巴瘤的疗效。

背景技术通常通过物理测量淋巴结直径来评估在犬淋巴瘤中施用环磷酰胺，阿霉素，长春新碱和泼尼松（CHOP）的多药物化疗方案的疗效。然而，尚未根据淋巴结大小与预后指标以及临床缓解期的长短或是否存在一致的相关性。在人类癌症的最新研究中，在治疗中期测量的RNA破坏与无病生存期增加相关，并在这项针对犬淋巴瘤患者的研究中进行了评估。在治疗前以及CHOP治疗的第3、6和11周采集细针抽吸样品。从这些样品中分离RNA，并使用安捷伦生物分析仪进行评估。对来自所得电泳图谱的数据进行RNA破坏测定（RDA）分析。结果增加的RNA破坏指数（RDI）分数与无进展生存期的改善显着相关。结论预测化疗期间早期复发的风险可以通过减少无效治疗而使兽医患者受益，并可以使兽医学家更早地转向更有效的药物治疗方案。